STERIS plc

  • TickerSTE
  • ISINIE00BFY8C754
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • No one knows just how the COVID-19 plays out, but yes, at some point this too will pass. We would expect volatility to continue and headlines to trump (pun not intended) trends. The divergence between Technology and the Energy, Materials, and Industrials Sectors has been disturbing to us for some time. Small-Caps and emerging markets have been lagging the Tech heavy S&P 500 significantly as well. • We believe that widening spreads between high-yield corporates and 10-yr Treasuries could be the canary in the coal mine. A decisive break above the trend line may usher in a mu...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A few Consumer Discretionary names continue to act well. The list is thinning of attractive names though. (ex. FOXF, UEIC, DECK, CHDN, WING, YUM, BOOT, RCI, POOL, DLTR, and AAN) • A number of Health Care Sector names are attractive. (ex. MASI, TFX, CNMD, STE, CRVL, LNTH, HAE, COO, WST, RGEN, ANIK, NEO, and TECH) • Attractive Technology and Services names include: MANH, CDNS, ANSS, AGYS, TTEC, CLGX, MMS, and KBR

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Jake Strole

Morningstar | Steris' Narrow Economic Moat Supported By Elevated Investment in Fiscal 2020

We believe management’s investment strategy at Steris has been instrumental in forming a narrow-moat enterprise, deploying capital into internal initiatives and acquisitions to fortify the firm’s position as the global leader in infection prevention. The 1997 purchase of Isomedix formed the foundation upon which the company built its leading position in contract sterilization services in the healthcare industry, capped by the acquisition of U.K.-based Synergy Health in 2015. We think this piece of the business represents the widest-moat segment of the firm, as switching costs and regulator...

Jake Strole

Steris' Narrow Economic Moat Supported By Elevated Investment in Fiscal 2020

Narrow-moat Steris finished its fiscal 2019 on a remarkably strong note, posting 9% constant currency organic growth in the quarter and 7.6% for the year. As we update and roll our model, we'll likely raise our $104 per share fair value estimate by a mid-single-digit percentage as some positives are offset by a higher-than-expected capital investment program over the next several years. Strength was broad based across its four businesses, which lays the groundwork for a solid 2020. Our expectati...

Jake Strole

Morningstar | Steris Posts Strong Finish to Fiscal 2019; Initial 2020 Outlook Ahead of Our Expectations

Narrow-moat Steris finished its fiscal 2019 on a remarkably strong note, posting 9% constant currency organic growth in the quarter and 7.6% for the year. As we update and roll our model, we'll likely raise our $104 per share fair value estimate by a mid-single-digit percentage as some positives are offset by a higher-than-expected capital investment program over the next several years. Strength was broad based across its four businesses, which lays the groundwork for a solid 2020. Our expectations for the coming year fell at the lower end of management's outlook, which calls for 5% to 6% or...

Jake Strole

Steris Posts Strong Finish to Fiscal 2019; Initial 2020 Outlook Ahead of Our Expectations

Narrow-moat Steris finished its fiscal 2019 on a remarkably strong note, posting 9% constant currency organic growth in the quarter and 7.6% for the year. As we update and roll our model, we'll likely raise our $104 per share fair value estimate by a mid-single-digit percentage as some positives are offset by a higher-than-expected capital investment program over the next several years. Strength was broad based across its four businesses, which lays the groundwork for a solid 2020. Our expectati...

STERIS increases its risk exposure and slightly lowers to Neutral

STERIS (US), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date January 12, 2021, the closing price was USD 192.06 and its expected value was estimated at USD 188.50.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch